Page 55 - 51 the significance--29.2_opt

28. Villanueva G, Baldwin D. Rosiglitazone therapy of posttransplant diabetes mellitus.
Transplantation 2005;80(10):1402-5.
29. Bayer. Glucobay SPC. 2009.
30. Charpentier G, Riveline JP, Varroud-Vial M. Management of drugs affecting blood
glucose in diabetic patients with renal failure. Diabetes Metab 2000;26 Suppl 4:73-85.
31. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes
Care 2003;26(10):2929-40.
32. Eli-Lilly. Byetta 5 micrograms solution for injection SPC. 2009.
33. NovoNordisk. Victoza 6 mg/ml solution for injection in pre-filled pen. 2009.
34. Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB. Liraglutide,
a long-acting glucagon-like peptide-1 analog, reduces body weight and food
intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin,
does not. Diabetes 2007;56(1):8-15.
35. Jones MC. Therapies for diabetes: pramlintide and exenatide. Am Fam Physician
2007;75(12):1831-5.
36. Merck Sharpe & Dohme Ltd. Januvia Summary of Product Characteristics. 2009.
®
®
37. Novartis Europharm Ltd. Galvus Summary of Product Characteristics. 2009.
38. Bristol-Myers Squibb Pharmaceuticals Ltd and AstraZeneca EEIG. Onglyza Summary
®
of Product Characteristics. June, 2009.
39. Bristol-Myers Squibb Pharmaceuticals Ltd and AstraZeneca EEIG. Onglyza Prescribing
®
Information. 2010.
40. Merck Sharpe & Dohme Ltd. Januvia US Prescribing Information. 2010.
®
41. Novartis Europharm Ltd. Galvus Prescribing Information. 2010.
®
42. Goldstein BJ. Clinical translation of “a diabetes outcome progression trial”: ADOPT
appropriate combination oral therapies in type 2 diabetes. J Clin Endocrinol Metab
2007;92(4):1226-8.
43. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive
glucose control in type 2 diabetes. N Engl J Med 2008;359(15):1577-89.
44. Smith RJ, Nathan DM, Arslanian SA, Groop L, Rizza RA, Rotter JI. Individualizing
therapies in type 2 diabetes mellitus based on patient characteristics: what we
know and what we need to know. J Clin Endocrinol Metab 2010;95(4):1566-74.
45. Gavin JR, 3rd, Bohannon NJ. A review of the response to oral antidiabetes agents in
patients with type 2 diabetes. Postgrad Med 2010;122(3):43-51.

55